Dole Food Company Releases 2020 Corporate Responsibility & Sustainability Report
22.4.2020 16:00:00 EEST | Business Wire | Press release
Dole Food Company announced today the release of its 2020 Corporate Responsibility & Sustainability Report. The report unveils the organization’s new sustainability framework, “The Dole Way,” along with the company’s first-ever enterprise-wide sustainability goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422005205/en/
Dole Fresh Fruit, Pineapple Farm (Photo: Business Wire)
“Since our founding, Dole has strived to deliver the best of which we are capable—in both our products and how we produce them,” stated Johan Linden, CEO of Dole. “The need for healthy food choices has never been more evident than during these past weeks as we adapt under this global pandemic. The journey and dedication to be a responsible citizen of our communities as well as a good steward of our land will continue into our future and Dole will remain steadfast in being honest and transparent about our efforts and our impacts in supplying wholesome food across the globe.”
“Of course,” Linden continued, “our stakeholders expect this of us, but even more we expect this of ourselves; to engage in open dialogue, including critical voices, to make a measurable and meaningful difference for people and the planet, and to constantly evaluate and improve. It’s what we believe is the right way to do business.”
Dole’s sustainability report outlines an ambitious slate of initiatives under the Dole Way framework focused on tangible action directed towards five key goals:
- More than ever, Dole understands our responsibility to positively impact underserved communities and promises to donate no less that 2,500 tons of fresh fruit and produce by 2025.
- Dole will effect valuable long-term change by declaring a social premium for Dole branded bananas and pineapple. This social investment will be directed by company organizations and independent foundations that have operated in Dole’s Latin American production areas for decades and will be invested in the communities according to local needs.
- Dole produce is grown in areas where water is becoming increasingly scarce, and Dole is committed to reduce water usage while improving water quality in its operations.
- Dole will continue to take action to promote healthy eating and nutrition education, with a special focus on youth. At its core, this is a promise to support people living longer and healthier lives.
- Dole recognizes that climate change is real and that the food and agriculture industries have a role to play in mitigating its effects. Dole will focus on decreasing its carbon footprint by ensuring new vessels include efficiency upgrades and working towards achieving net zero carbon emissions at farm level by 2030.
Other important sustainability targets include ensuring all packaging materials used in Dole’s banana and pineapple businesses are either recyclable or compostable by 2025, and introducing blockchain or similar technology in all operations to bring about a step-change in food safety and transparency.
Reporting on the impacts of Dole’s responsibility and sustainability goals is also of critical importance.
“This report and our goals are a new milestone in our sustainability pursuit, and farming is at the heart of that transformation. As farmers, we are facing the reality of climate change and are joining all other concerned people and businesses willing to tackle this challenge in our supply chain,” said Xavier Roussel, Vice President of Sustainability. “We will build on our learning—both in precision farming and organic agriculture—to deliver on our commitments in alliance with our business partners and other stakeholders. As an employer we will continue to make a difference in the lives of our employees and local communities and make a positive impact both within our farm borders and beyond.”
Added Roussel, “Dole is absolutely committed to being part of the community of concerned citizens taking on the sustainability challenge.”
To view all Dole’s achievements and goals click the link to the 2020 Corporate Responsibility & Sustainability Report click here.
About Dole Food Company
Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422005205/en/
Contact information
US Contact: William Goldfield
818-874-4647
william.goldfield@dole.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
